$MDGL earnings report

Madrigal reports $431.3 million of third-quarter 2026 Rezdiffra net sales, 50% year-over-year growth, and its first quarter of profitability. AlphAI read Madrigal Pharmaceuticals's Third-quarter 2026 filing as strong.

Third-quarter 2026

AlphAI · Earnings readMDGL · Third-quarter 2026 · ended Sept. 30, 2026

Madrigal reports $431.3 million of third-quarter 2026 Rezdiffra net sales, 50% year-over-year growth, and its first quarter of profitability.

✓Strong quarter

Rezdiffra net sales grew 50% year over year to $431.3 million, net income was $55.4 million versus a prior-year net loss, and the company reported $961.8 million of cash, cash equivalents, restricted cash and marketable securities.

Revenue
$431M
50% y/y
Rezdiffra
$431M
50% y/y
EPS · GAAP
$1.83

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Third-quarter 2026 net revenuesGAAP$431.3M–50%
Third-quarter 2026 Rezdiffra net salesGAAP$431.3M–50%
Year-to-date Rezdiffra net salesGAAP$1.1B––
Third-quarter 2026 operating expensesGAAP$375.3M––
Third-quarter 2026 non-cash stock-based compensation expenseGAAP$38.9M––
Third-quarter 2026 cost of salesGAAP$37.8M––
Third-quarter 2026 R&D expensesGAAP$71.8M––
Third-quarter 2026 SG&A expensesGAAP$265.7M––
Third-quarter 2026 net incomeGAAP$55.4M––
Third-quarter 2026 basic earnings per shareGAAP$1.90 per basic share––
Third-quarter 2026 diluted earnings per shareGAAP$1.83 per diluted share––
Patients on Rezdiffra as of Sept. 30, 2026othermore than 55,850 patients–nearly doubling from 3Q25
U.S. F2-F3 MASH addressable patients through June 30, 2026othermore than 530,000 addressable patients––

Segments

SegmentRevenueq/qy/y
RezdiffraIncreased demand for Rezdiffra in the U.S. in 2026.$431.3M–50%

What drove it

  • Net revenue growth was driven by increased demand for Rezdiffra in the U.S. in 2026.
  • More than 55,850 patients were on Rezdiffra as of Sept. 30, 2026, reflecting continued prescriber adoption and patient demand.
  • The U.S. F2-F3 MASH market grew to more than 530,000 addressable patients through June 30, 2026.
  • SG&A expense increased with continued commercial investment, including endocrinology field-force headcount expansion and direct-to-consumer marketing.
  • Cost of sales increased primarily because of higher royalties payable to Roche resulting from increased Rezdiffra net sales.

Concerns

  • SG&A expenses increased to $265.7 million from $209.1 million, driven by commercial investment.
  • Cost of sales increased to $37.8 million from $18.1 million, primarily reflecting higher royalties payable to Roche.
  • The company cited risks related to commercialization, regulatory approvals, clinical-trial enrollment and outcomes, indebtedness and debt covenants, market demand, competitors, and cyber-attacks.

What to watch

  • Initiation of the MAESTRO-CSPH Phase 3 outcomes trial is expected in the first half of 2027, subject to regulatory discussions.
  • MAESTRO-NASH OUTCOMES data are expected late 2027.
  • Madrigal plans for MAESTRO-CSPH to enroll more than 2,000 F4c patients.
  • The company stated that the U.S. F2-F3 MASH market is on track for more than 30% growth by YE26.
  • Rezdiffra prescriber adoption, patient demand, and commercial spending remain key operating indicators.

Balance sheet and cash flow

  • Cash, cash equivalents, restricted cash and marketable securities were $961.8 million as of Sept. 30, 2026, compared to $988.6 million as of Dec. 31, 2025.

Analysis

Third-quarter results show continued commercial momentum for Rezdiffra. Net revenues and Rezdiffra net sales were $431.3 million, up 50% from $287.3 million in the comparable prior-year period. Madrigal stated that more than 55,850 patients were on therapy as of Sept. 30, 2026, nearly doubling from 3Q25, while year-to-date Rezdiffra net sales reached $1.1 billion.

The company achieved its first quarter of profitability, reporting net income of $55.4 million, or $1.90 per basic share and $1.83 per diluted share. This compared with a net loss of $114.2 million, or $4.01 per basic and diluted share, in the comparable prior-year period. Operating expenses declined to $375.3 million from $401.2 million, although the release did not provide an operating-income or gross-margin figure.

Expense mix shifted materially. R&D expenses declined to $71.8 million from $174.0 million, primarily because the comparable prior-year period included a one-time, upfront business-development expense of $117.3 million. This was partly offset by higher SG&A expenses of $265.7 million, reflecting endocrinology field-force expansion and direct-to-consumer marketing, and cost of sales of $37.8 million, primarily due to higher Roche royalties associated with greater Rezdiffra sales.

Madrigal ended the period with $961.8 million of cash, cash equivalents, restricted cash and marketable securities, compared with $988.6 million as of Dec. 31, 2025. The release provided no financial outlook. Operationally, management highlighted a U.S. F2-F3 MASH market of more than 530,000 addressable patients through June 30, 2026, its planned MAESTRO-CSPH Phase 3 trial initiation in the first half of 2027, and expected MAESTRO-NASH OUTCOMES data in late 2027.

Management, verbatim

Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market. Our latest analysis shows the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026, reinforcing how quickly this category is developing and the significant runway ahead.

Bill Sibold, Chief Executive Officer of Madrigal

Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH. MAESTRO-CSPH is our new, Phase 3, practice-shaping trial that we expect will extend our competitive advantage and strengthen our long-term leadership in this rapidly growing market.

Bill Sibold, Chief Executive Officer of Madrigal

Not in the filing

stated, not guessed
  • Financial tables referenced as "tables follow" were not included in the provided filing text.
  • Gross profit and gross margin.
  • Operating income or loss and operating margin.
  • Income tax expense or benefit and tax rate.
  • Cash flow from operations.
  • Free cash flow.
  • Debt balance and debt maturities.
  • Share repurchases, dividends, or other capital-return activity.
  • Non-GAAP financial measures, including non-GAAP EPS.
  • Quarter-over-quarter comparisons for reported financial metrics.
  • Financial guidance for revenue, gross margin, operating expenses, tax rate, or earnings.
  • Prior-period figures for year-to-date Rezdiffra net sales and addressable-patient metrics.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about MDGL earnings dates

When is Madrigal Pharmaceuticals's next earnings date?
AlphAI has no date for MDGL yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.